Sign in3 stories
The S-1, filed September 9, 2026, covers shares and pre-funded warrants sold to institutional investors in an August 2026 private placement.
SEC filing
The company anticipates gross proceeds of about $150 million from investors and says cash should last through 2028 as it advances ML-007C-MA.
SEC filing
The 210/3 mg BID dose reduced PANSS total scores versus placebo in Phase 2 ZEPHYR, and MapLight said it will advance to an additional pivotal study ahead of an end-of-Phase 2 FDA meeting.
SEC filing